Physician profile
Reed Hogan
NPI 1356504682
$35,099.17
in general payments reported to CMS, 2019-2025
34 companies · $27K in 2025
The $27K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $560 · 2021: $761 · 2022: $2,386 · 2023: $1,507 · 2024: $2,686 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Consulting Fee: $4,456 · Food and Beverage: $2,348 · Travel and Lodging: $1,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,900.00 |
| Consulting Fee | $4,456.00 |
| Food and Beverage | $2,348.23 |
| Travel and Lodging | $1,391.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $24,686.93 | 2022-2025 | Interstim |
| Axonics, INC. | $4,529.17 | 2021-2024 | Axonics |
| Genzyme Corporation | $2,394.76 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $551.61 | 2020-2025 | Xifaxan |
| Abbvie INC. | $495.17 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $310.61 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $279.31 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $228.60 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $220.12 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $202.63 | 2022-2023 | Dupixent |
| Olympus America INC. | $147.65 | 2019-2020 | |
| Ambu INC. | $138.02 | 2021 | |
| Pentax of America, INC. | $130.98 | 2022 | |
| Mauna Kea Technologies, INC. | $108.82 | 2021 | |
| Exact Sciences Corporation | $98.12 | 2023 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $90.90 | 2020-2023 | Linzess |
| Fujifilm Healthcare Americas Corporation | $68.34 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $64.28 | 2022-2025 | |
| Janssen Biotech, INC. | $58.97 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $50.45 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $45.73 | 2023-2024 | Dificid |
| Pfizer INC. | $41.51 | 2019 | |
| Braintree Laboratories, INC. | $31.34 | 2023 | Sutab, Suflave |
| Redhill Biopharma INC. | $23.40 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.12 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.06 | 2023 | Rebyota |
| Endogastric Solutions, INC | $15.95 | 2022 | |
| Aimmune Therapeutics, INC. | $14.43 | 2025 | Vowst |
| Shire North American Group INC | $13.63 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.54 | 2019 | |
| Allergan, INC. | $11.02 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$42,934.60 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Hogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.